Ameriprise Financial Inc. Cuts Stock Holdings in Johnson & Johnson $JNJ

Ameriprise Financial Inc. cut its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.6% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 13,200,118 shares of the company’s stock after selling 82,472 shares during the period. Johnson & Johnson accounts for 0.5% of Ameriprise Financial Inc.’s holdings, making the stock its 25th biggest position. Ameriprise Financial Inc. owned about 0.55% of Johnson & Johnson worth $2,017,033,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Brighton Jones LLC lifted its stake in shares of Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after buying an additional 6,332 shares in the last quarter. United Bank grew its holdings in Johnson & Johnson by 110.7% in the 1st quarter. United Bank now owns 9,279 shares of the company’s stock valued at $1,539,000 after buying an additional 4,876 shares in the last quarter. Cookson Peirce & Co. Inc. acquired a new position in Johnson & Johnson in the first quarter valued at approximately $208,000. Azimuth Capital Investment Management LLC lifted its position in Johnson & Johnson by 1.6% in the first quarter. Azimuth Capital Investment Management LLC now owns 98,691 shares of the company’s stock valued at $16,367,000 after buying an additional 1,548 shares during the last quarter. Finally, Horizon Investments LLC lifted its stake in Johnson & Johnson by 8.6% during the first quarter. Horizon Investments LLC now owns 27,843 shares of the company’s stock worth $4,617,000 after purchasing an additional 2,216 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages recently commented on JNJ. Sanford C. Bernstein raised their target price on Johnson & Johnson from $172.00 to $193.00 and gave the company a “market perform” rating in a report on Monday, October 6th. Stifel Nicolaus lifted their price objective on shares of Johnson & Johnson from $165.00 to $190.00 and gave the stock a “hold” rating in a research report on Wednesday, October 15th. Cowen reissued a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, October 14th. Bank of America lifted their price target on Johnson & Johnson from $198.00 to $204.00 and gave the stock a “neutral” rating in a report on Wednesday, October 15th. Finally, BMO Capital Markets restated an “outperform” rating on shares of Johnson & Johnson in a research report on Thursday. Four research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $206.65.

Johnson & Johnson Price Performance

Shares of JNJ opened at $211.65 on Friday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The firm has a 50-day simple moving average of $196.09 and a 200-day simple moving average of $177.08. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $212.27. The company has a market capitalization of $509.93 billion, a price-to-earnings ratio of 20.43, a price-to-earnings-growth ratio of 2.34 and a beta of 0.36.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The company had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. On average, equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th were issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend was Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is currently 50.19%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.